Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q7/00—Preparations for affecting hair growth

Definitions

• the present invention relates to the use of at least one non-photosynthetic non-fruitful filamentous bacterial extract as a protective and / or stimulating agent for the activity and / or proliferation of gamma-delta T lymphocyte cells ( ⁇ T cells) in a composition containing a cosmetically or pharmaceutically acceptable medium.
• composition will find applications to promote the tissue repair of the skin, to rebalance epidermal proliferation and differentiation disorders that appear with lack of sleep, to improve the appearance of the hair and limit hair loss.
• Human skin consists of a superficial compartment, the epidermis and a deep compartment, the dermis.
• the epidermis is composed mainly of three types of cells which are keratinocytes (majority), melanocytes and Langerhans cells. Each of these cell types contributes, by its own functions, to the essential role played in the body by the skin, in particular the protective role of the body against external aggressions.
• the dermis provides the epidermis with a solid support. It is also its nurturing element. It consists mainly of fibroblasts and an extracellular matrix composed mainly of collagen, elastin and a fundamental substance. There are also leucocytes, mast cells and tissue macrophages. Finally, the dermis is crossed by blood vessels and nerve fibers.
• the skin constitutes a barrier against external aggressions, in particular chemical, mechanical, and as such a number of reactions of defense against the environment (climate, ultraviolet rays, tobacco, pollution ...) and / or xenobiotics (as for example some drugs) occur at its level.
• TCR T cell receptor
• 95% of the lymphocyte population consists of lymphocytes whose T-cell antigen receptors are transmembrane hetero-dimers composed of an alpha and beta ( ⁇ T) chain. Only 5% of lymphocytes express gamma and delta chains ( ⁇ T), this population was highlighted by Tonegawa et al. in 1984.
• ⁇ T lymphocytes are mainly located either in the blood (for the V ⁇ 2 subtype) or in the epidermis and the mucous membranes (for the resident V ⁇ 1 subtype). They express the CD3 receptors and the TCR gamma-delta receptors (respectively with two variable regions depending on their circulating localization: Vy9V ⁇ 2 or resident: V ⁇ 9V ⁇ 1) and are often CD4 (-) CD8 (-), their activation is not restricted.
• major histocompatibility complex MHC
• the gamma chain is encoded by chromosome 7 and the delta chain by the 14th.
• ⁇ T lymphocytes constitute a T lymphocyte population whose analysis of the structural characteristics has modified the knowledge on the interactions between the T cell and its antigen. The importance of the immunoregulatory functions exerted by these cells opens new perspectives in the understanding of the mechanisms that contribute to the maintenance of the homeostasis of the immune system. ⁇ T lymphocytes seem to intervene very early in the regulation of innate immunity.
• IGFs Insulin Growth Factors
• GH Growth Hormone
• GH acts on the peripheral organs and the brain either directly or indirectly by stimulating the synthesis of growth factors, such as insulin-like growth factors (IGF I and II) or epidermal growth factor (EGF) or that of their receptors.
• IGF I and II insulin-like growth factors
• EGF epidermal growth factor
• the direct action of GH is of the anti-insulin type by promoting lipolysis in the adipose tissue.
• GH stimulates the incorporation of amino acids into proteins, cartilage and bone growth (stature growth), and cell proliferation of many organs, including the skin.
• Growth hormone and other somatotropic hormones are able to maintain its youthful appearance in the body. They intervene, indeed, in the management of its metabolism, determining not only the final size of the adult body but giving again, volume, tone and firmness to the organs and tissues, particularly to the muscles.
• growth hormone is involved in everything that provides a good self-image and a positive mind. It strengthens the body and makes the back straighter, developing the muscles of the shoulders and pelvis. It also decreases fat, especially in the belly, increases libido and sexual energy, regrowth and hair coloring, as well as elasticity of the skin. Perhaps less noticeable but equally beneficial, its effects can be seen in a better resistance to effort, a less prolonged and more profitable sleep, a balanced blood pressure, a better visual, auditory and cerebral acuity.
• GH is pulsatile secretion and this character is a determining factor for a large number of biological effects of the hormone.
• IGFI Insulin like Growth Factor 1
• Somatomedin C 1 The growth hormone levels circulating in the blood stimulate the production, from the liver, of another hormone, IGFI (Insulin like Growth Factor 1), whose role as a mediator allows the growth hormone of develop its positive effects. Measuring the level of IGFI, also known as Somatomedin C 1, is considered safer than that of GH, virtually undetectable by day in humans.
• the liver is the most important site for producing IGFs, but many cells are able to produce IGFs.
• IGF1 and IGF2. Two types are classically described: IGF1 and IGF2. These are two peptides whose amino acid sequence is similar to that of insulin, hence their name.
• the PIGF1 receptor has a shared affinity with insulin.
• IGFI IGFI alone stimulates the proliferation of keratinocytes (Neely EK - Insulin-like growth factors are mitogenic for human keratinocytes and squamous cell carcimona - J Invest Dermatol 1991 Jan; 96 (1) : 104-10). With regard to fibroblasts, it is also known that IGFI stimulates the synthesis of GAGs, and the synthesis of collagen. In addition, studies have shown a significant participation of IGFs in healing. Finally, a study conducted in vivo in humans has shown that a percutaneous treatment with IGF1 for a month resulted in an argumentation of cutaneous thickness. Decreased IGFI expression has also been shown to be associated with increased hair loss (Tang et al, 2003, J. Am Dermatol, Aug. 49 (2): 229-33).
• an extract of Vitreoscilla filiformis total or in the form of an LPS fraction, stimulates and / or protects the ⁇ T cells and that thus this extract can induce the secretion and the release of IGFI in the skin.
• This control of the release of IGFI by keratinocytes contributes to the maintenance of epidermal homeostasis which regulates in particular the equilibrium between proliferation and differentiation of epidermal cells.
• the present invention relates to the use of at least one non-photosynthetic non-fruitful filamentous bacterial extract to maintain and / or restore the equilibrium between proliferation and differentiation of epidermal cells.
• the bacterial extracts that can be used in this invention will be chosen from non-photosynthetic and non-fruiting filamentous bacteria as defined according to the Bergey's Manual of Systemic Bacteriology classification, volume 3, section 23, 9 th edition 1989.
• bacteria belonging to the order Beggiatoales and in particular the bacteria belonging to the genus Beggiotoa, such as, for example, various strains of Beggiotoa alba according to the definition of B. alba corresponding to the old names Beggiotoa arachnoidea. , B. gigantea, ⁇ . leptomiformis, B. minima, B. mirabilis from Bergey's manual, 8 th edition.
• the bacteria belonging to the genus Vitreoscilla which is known to be close and often difficult to discern from the genus Beggiatoa.
• the bacteria that have just been defined, and many of which have been described generally have an aquatic habitat, and can be found especially in thermal springs.
• Among the usable bacteria include, for example, Vitreoscilla beggiatoides (ATCC 43181) and Beggiatoa alba (ATCC33555).
• Vitreoscilla filiformis extract in particular the ATCC 15551 strain, its metabolites and its fractions are claimed.
• extract of non-photosynthetic and non-fruiting filamentous bacteria it is meant both the culture supernatant, the biomass obtained after culturing said bacteria, the envelopes or fractions of envelopes, or the extracts of the biomass obtained by treatment of this biomass.
• said bacteria can be cultured and then separated from the biomass obtained, for example by filtration, centrifugation, coagulation and / or freeze-drying.
• the bacteria are concentrated by centrifugation.
• the biomass obtained is autoclaved.
• This biomass can be lyophilized to form what is called the freeze-dried extract. Any method of lyophilization known to those skilled in the art is used to prepare this extract.
• the supernatant fraction of this biomass can also be filtered in a sterile container to remove suspended particles.
• Envelopes or fractions of envelopes are called envelopes.
• LPS lipopolysaccharide fraction
• the extract may also relate to lipid A which can be obtained according to the process described in EP 1 531 158.
• the bacterial extract may be used in the form of a freeze-dried powder of 0.001% to 5% and preferably of 0.05% to 3% in liquid compositions and up to 10% in powder compositions.
• a protector and / or stimulator of ⁇ T lymphocytes in the skin and / or mucous membranes leads to the increased release of IGFI by epidermal cells and promotes the physiological proliferation of keratinocytes and / or decreases epidermal differentiation.
• the present invention also relates to the cosmetic use of a nonsynthetic non-photosynthetic filamentous bacterial extract to mimic the effect of sleep on cell renewal. epidermal or to either complement the effect of sleep on the skin during a normal rest or, to supplement the dysfunction of skin epidermal functions that may occur during a lack of sleep.
• the use according to the invention will thus more specifically aim to mimic the effects of sleep on epidermal cellular renewal to prevent and / or correct the cutaneous effects characteristic of lack of sleep and / or to stimulate the skin during the absence of sleep and induce the renewal of epidermal cells.
• the use according to the invention makes it possible to prevent and / or treat the cutaneous manifestations generated by the slowing down of the renewal of the cells, thus leads to the cellular regeneration of the epidermis and improves the appearance of the surface of the skin.
• the consequences of this activity is that the use of non-photosynthetic filamentous bacterial extract non-fruiting according to the invention on a subject in lack of sleep makes it possible more particularly to treat drawn and / or dug features, to even out the complexion. .
• the present invention relates to a cosmetic treatment method for erasing the cutaneous signs of fatigue by stimulating the regeneration of epidermal cells, characterized in that it comprises the application to the face of at least one extract non-photosynthetic filamentous bacterium non-fruiting.
• the invention of the non-photosynthetic filamentous bacterial extract which is not fruiting also makes it possible to prevent and / or treat hair disorders such as a change in the density, the quantity or the quality of the hair, as a consequence of, for example, a slowing down, stopping growth or falling hair follicles.
• the present invention relates to the use of at least one extract of non-photosynthetic filamentous bacterium non-fruiting to prevent the thinning of the keratinous fiber and / or induce the growth of hair and / or hair to induce regrowth of hair or denser hair.
• the invention also relates to the use of an extract of non-photosynthetic filamentous bacterium non-fruiting as an agent for inducing and / or stimulating the growth of keratinous fibers, human hair or hairs, in particular human and / or braking their fall and / or increase their density.
• the keratinous fibers By increasing the density of the keratinous fibers, and in particular the capillary density, it is intended to increase the number of keratin fibers, in particular the hair, per cm 2 of skin such as the scalp.
• non-photosynthetic filamentous bacterial extract non-fruiting relates to hair treatment compositions (shampoo, lotion, masks ...) for limiting and / or preventing hair loss and thus treating alopecia of whatever nature it is and / or promote the growth of healthy hair.
• the cosmetic use according to the invention of an extract of non-photosynthetic filamentous bacterium non-fruiting can be done using a cosmetic composition care and / or makeup of keratin fibers.
• the invention also applies to keratinous fibers of mammals of the animal species (dog, horse or cat for example).
• the human keratinous fibers to which the invention applies are in particular the hair, the eyebrows, the eyelashes, the beard and mustache hairs. More specifically, the invention is applicable to human hair and / or eyelashes.
• the subject of the present invention is also a process for the cosmetic treatment of human keratinous fibers and / or the skin from which said fibers, including the scalp, emerge, intended in particular to stimulate the growth of human keratinous fibers such as the hair and your cilia being human and / or curbing their fall, characterized in that it consists in applying to the human keratin fibers and / or the skin from which said fibers emerge, a cosmetic composition comprising an effective amount of 'an extract non-photosynthetic filamentous bacteria non-fruiting, to leave it in contact with the keratinous fibers and / or the skin from which the said fibers emerge, and optionally to rinse the keratinous fibers and / or said skin.
• This treatment method has the characteristics of a cosmetic process insofar as it makes it possible to improve the esthetics of the keratinous fibers and in particular the hair and the eyelashes by giving them a greater vigor and an improved appearance. In addition, it can be used daily for several months, without a medical prescription. More specifically, the subject of the present invention is a process for the cosmetic care of human hair and / or scalp, with a view to improving their state and / or their appearance, characterized in that it consists in applying to the hair and or or the scalp, a cosmetic composition comprising an extract of non-photosynthetic filamentous bacterium non-fruiting, to leave it in contact with the hair and / or the scalp, and possibly to rinse the hair and / or the scalp.
• the subject of the invention is also a process for the cosmetic care and / or makeup of these human eyelashes, with a view to improving their state and / or their appearance, characterized in that it consists in applying a mascara composition comprising an extract non-photosynthetic filamentous bacterium non-fruiting and to leave it in contact with the eyelashes.
• This mascara composition can be applied alone or as an undercoat of a conventional pigmented mascara and removed as a conventional pigmented mascara.
• compositions used according to the invention can be administered orally, enterally or else topically, preferable topical administration.
• compositions may be in any suitable form such as an oral solution, capsules, dragee, soft or hard capsule, tablets to swallow or chewable, granules to dissolve, syrup, solid or liquid food ...
• compositions may also be in the galenical forms conventionally used for topical application and especially in the form of lotion or serum-type dispersions, of liquid or semi-liquid consistency emulsions of the milk type, obtained by dispersion of a fatty phase. in an aqueous phase (O / W) or conversely (W / O), or suspensions or emulsions of soft, semi-solid or solid consistency of the cream or gel type, or multiple emulsions (W / O / W or H / E / H), microemulsions, nanoemulsions, vesicular dispersions of ionic and / or nonionic type, or wax / aqueous phase dispersions.
• These compositions are prepared according to the usual methods. It may also be in the form of a transdermal system allowing active or passive release of the active (s) by transdermy, for example patch or gel patch (hydrogel).
• the composition used according to the invention may thus constitute a composition for treating or caring for the skin (including the scalp), keratin fibers (hair, eyelashes, eyebrows), nails or lips, or a protective composition.
• solar or artificial tanning, or a cleanser or makeup remover of the skin, hair, eyebrows or eyelashes, a deodorant product or a perfume compound.
• It is then generally not colored or weakly colored, and it may optionally contain cosmetic or dermatological active ingredients.
• It can then be used as a skin or lip care base (lip balms, protecting the lips from cold and / or sun and / or wind) as a day or night care cream for the skin of the skin. face and / or body. It may, in addition, be in the form of shampoo treatment or not, dye or not, and conditioner.
• the composition used according to the invention may also constitute a colored cosmetic composition and in particular a makeup composition for the skin, keratinous fibers (hair or eyelashes) and / or mucous membranes, in particular a foundation, a blush, a makeup with cheeks or eyes, a concealer compound in a stick, a lipstick or a lip gloss, optionally having care or treatment properties.
• a colored cosmetic composition (beige or green) intended to correct the color of the complexion.
• composition used according to the invention may also comprise active agents which will be chosen by those skilled in the art so that they do not harm the effect of the non-photosynthetic filamentous bacterial extract. fruiting.
• Examples' 1 of soothing agents used in the compositions of the invention include:
• Beta-glycyrrhetinic acid the extracts containing them, for example extract of Glycyrrhiza glabra (licorice) and complexes containing them, such as the allantoin / glycyrrhetinic acid complex; • plankton, freeze-dried or not, their extracts and complexes;
• Xanthine derivatives such as diethylaminoethyl theophylline hydrochloride and caffeine; • waters and extracts (for example aqueous, hydro-alcoholic or hydroglycolic) of flowers and plants, such as blueberry water, chamomile water, mint water, linden water, rose water , Rosaceae extracts (ex: Rosa gallica, Rosa canina), peony extracts, hawthorn extracts, millefeuille extracts, mauve extracts, marigold extracts, melilot extracts, sage extracts , elderberry water, ginkgo biloba extract, arnica extract, oregano extract, green tea extract, water lily flower extract, iris extract, bark extract birch, extracts Aloe vera;
• waters and extracts for example aqueous, hydro-alcoholic or hydroglycolic of flowers and plants, such as blueberry water, chamomile water, mint water, linden water, rose water , Rosaceae extracts
• Asian acid and plant extracts containing it such as Centella asiatica
• fruit extracts such as pineapple extract, papaya extract; guava; "Algae, in particular of the Laminaria type (for example red or brown);
• Pyrrolidone carboxylates and in particular zinc (Zn-PCA) or copper (Cu-PCA);
• Fucose-containing polysaccharides such as FUCOGEL 1000, sold by Solabia (aqueous solution comprising 1% of polysaccharide solids comprising fucose, galactose and galacturonic acid);
• Electrolytes and in particular an aqueous mixture comprising from 30 to 35% of magnesium chloride, from 20 to 28% of potassium chloride, from 3 to 10% of sodium chloride, from 0.2 to 1% of chloride of calcium, from 0.1 to 0.6% of magnesium bromide and from 0.1 to 0.5% of insolubles, the so-called mixture being here called "Dead Sea Bath Salts Mixture" Because it corresponds to the main salts contained in the Dead Sea;
• galactolipids for example from oats, such as for example digalactosyl diglyceride or monogalactosyl diglyceride;
• Amino acids, their derivatives and their salts such as the sodium salt of amino acids grafted onto cocoyl chains, marketed in the form of a mixture under the SEPICALM S name by the company SEPPIC, capryloylglycine sold under the name LIPACIDE C8G by the company SEPPIC and the mixture of capryloylglycine, cinnamon and sarcosine marketed under the name SEPICONTROL A5 by the company SEPPIC; TNF-alpha antagonists such as, for example, lisophylline, I ⁇ 802715, sulfasalazine, CDP-571 (anti-TNF-alpha antibody), MDL-201112;
• Substance P antagonists such as sendide, spantide II, and the peptides described in application EP-A-680749, the extracts of filamentous bacteria described in application EP-A-761204; • CGRP antagonists, such as CGRP 8-37, anti-CGRP antibodies, or plant extracts with CGRP antagonist activity (ex: Iris pallida).
• the divalent salts of strontium, zinc, manganese, magnesium and calcium such as those described in documents WO-A-96/19184, WO-A-96/19182 and WO-A-96/19228; and their mixtures.
• treating agent any compound capable of acting:
• ⁇ -hydroxy acids in particular salicylic acid and its derivatives (including n-octanoyl-5-salicylic acid); ⁇ -hydroxy acids, such as glycolic, citric, lactic, tartaric, malic or mandelic acids; urea; gentisic acid; oligofucoses; cinnamic acid; Saphora japonica extract; resveratrol and certain jasmonic acid derivatives; or on the enzymes involved in the desquamation or the degradation of the coméodesmosomes, the glycosidases, the stratum corneum chymotryptic enzym (SCCE) or even other proteases (trypsin, chymotrypsin-like).
• SCCE stratum corneum chymotryptic enzym
• chelating agents for mineral salts I ⁇ DTA; N-acyl-N, N ', N', ethylene diaminetriacetic acid; aminosulfonic compounds and in particular (N-2-hydroxyethylpiperazine-N-2-ethyl) sulfonic acid (HEPES); 2-oxothiazolidine-4-carboxylic acid derivatives (procysteine); glycine-type alpha amino acid derivatives (as described in EP-0 852 949), as well as the sodium methyl glycine diacetate marketed by BASF under the tradename TRILON M, honey, sugar derivatives such as O-octanoyl-6-D-maltose and N-acetylglucosamine By “moisturizing agent” is meant:
• ceramides compounds based on sphingoid, lecithins, glycosphingolipids, phospholipids, cholesterol and its derivatives, phytosterols (stigmasterol, ⁇ -sitosterol, campesterol), essential fatty acids, 1-2 diacylglycerol, 4-chromanone, pentacyclic triterpenes such as ursolic acid, petrolatum and lanolin; or a compound directly increasing the water content of the stratum corneum, such as thralose and its derivatives, hyaluronic acid and its derivatives, glycerol, pentanediol, sodium pidolate, serine, xylitol, lactate sodium, glycerol polyacrylate, ectoin and its derivatives, chitosan, oligo-
• composition according to the present invention comprising the desquamating and moisturizing agents mentioned above is advantageously intended for preventing or treating drying of the skin and in particular xeroses.
• depigmenting agents anti-pi ⁇ mentants or pro-pigmenting agents
• anti-glycation agent a compound that prevents and / or decreases the glycation of skin proteins, in particular dermal proteins such as coliagen.
• anti-glycation agents are the plant extracts of the family Ericaceae, such as a bilberry extract (Vaccinium angusifllium); ergothioneine and its derivatives; and the hydroxystilbenes and their derivatives, such as resveratrol and 3,3 ', 5,5'-tetrahydroxystilbene. These anti-glycation agents are described in applications FR 2 802 425, FR 2 810 548, FR 2 796 278 and FR 2 802420, respectively. Resveratrol is particularly preferred for use in this invention.
• the composition according to the invention comprising an anti-glycation agent as defined above may advantageously be used to prevent or treat the signs of skin aging, in particular to prevent or treat the loss of tonicity and / or elasticity of the skin. skin.
• NO-synthase inhibitors suitable for use in the present invention include in particular a plant extract of the Vitis vinifera species which is in particular marketed by Euromed under the name Leucocyanidines of extra grapes, or by Indena under the name Leucoselect ® , or finally by Hansen under the name Grape marc extract; a plant extract of the species Olea europaea which is preferably obtained from olive leaves and is in particular marketed by VINYALS in the form of a dry extract, or by Biologia & Technologia under the trade name Euroi BT; and an extract of a plant of the Gingko biloba species which is preferably a dry aqueous extract of this plant sold by Beaufour under the trade name Ginkgo biloba standard extract.
• composition according to the invention comprising a NO-synthase inhibitor as defined above can advantageously be used to prevent or treat the signs of skin aging and / or sensitive skin.
• composition according to the invention comprises an anti-seborrhoeic agent such as a 5 ⁇ -reductase inhibitor, it may especially be chosen from: retinoids, and in particular retinol;
• zinc salts such as lactate, gluconate, pidolate, carboxylate, salicylate and / or zinc cysteate;
• the 5 ⁇ -reductase inhibitor represents, for example, from 0.001% to 10%, and preferably from 0.01 to 5%, of the total weight of the composition according to the invention. When it contains such a compound, it is particularly well suited to prevent or treat seborrhea and / or phirsutism and / or alopecia androgen-dependent.
• inhibitors of lysyl and / or propyl hydroxylase that can be used in the composition according to the present invention are 2,4-diamino-pyrimidine 3-oxide or 2,4-DPO described in the patent application WO 96/09048 and 2,4-diamino-6-piperidino pyrimidine-3-oxide or "Minoxidil” described in US-4,139,619 and US-4,596,812.
• composition containing the lysyl and / or prolyl hydroxylase inhibitor and the DHEA derivative according to the invention is advantageously used for the prevention or treatment of alopecia.
• agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing their degradation include those which act:
• collagen such as extracts of Centella asiatica; asiaticosides and derivatives; ascorbic acid or vitamin C and its derivatives; synthetic peptides such as iamin, biopeptide CL or palmitoyloligopeptide marketed by SEDERMA; peptides extracted from plants, such as soybean hydrolyzate sold by Coletica under the trade name Phytokine ®; and plant hormones such as auxins and lignans.
• GAGs such as C- ⁇ -D-xylopyranoside-2-hydroxy-propane.
• elastin synthesis such as the extract of Saccharomyces cerevisiae marketed by LSN under the trade name Cytovitin ®; and the extract of the alga Macrocystis pyrifera sold by SECMA under the trade name Kelpadelie ®;
• glycosaminoglycan synthesis such as the fermentation of milk with Lactobacillus vulgaris, marketed by Brooks under the trademark Biomin ® yogourth®; the extract of the brown alga Padina Pavonica marketed by Alban Muller under the trade name HSP3 ®; and the extract of Saccharomyces cerevisiae available in particular from Silab under the trade name Firmalift® ® or from LSN under the trade name Cytovitin ®; - or on the synthesis of fibronectin, such as the extract of the zooplankton Salina marketed by SEPORGA under the trade name GP4G ®; yeast extract available especially from Alban Muller under the trade name DRIELINE ®; and the palmitoyl pentapeptide marketed by Sederma under the trade name Matrixyl ®; or on the inhibition of metalloproteinases (MMPs) such as, more particularly, MMPs 1, 2, 3, 9.
• MMPs metalloproteinases
• serine proteases such as leukocyte elastase or cathepsin G.
• serine proteases such as leukocyte elastase or cathepsin G.
• These include: the peptide extract of seeds of legume ⁇ Pisum sativum) sold by LSN under the trade name Parelastyl ®; heparinoids; and pseudodipeptides such as ⁇ 2- [acetyl- (3-trifluoromethyl-phenyl) -amino] -3-methyl-butyrylamino ⁇ -acetic acid and its derivatives.
• active stimulating epidermal macromolecules such as fillagrin and keratins
• active stimulating epidermal macromolecules such as fillagrin and keratins
• active stimulating epidermal macromolecules such as fillagrin and keratins
• active stimulating epidermal macromolecules such as fillagrin and keratins
• active stimulating epidermal macromolecules such as fillagrin and keratins
• Structurine® ® the extract of beech buds Fagus sylvatica marketed by Gattefosse under the trade name Gatuline ®
• the extract of the zooplankton Salina sold by SEPORGA under the trade name GP4G ®.
• composition according to the invention containing one or more of the above compounds is particularly suitable for use in the prevention or treatment of cutaneous signs of aging, in particular the loss of firmness and / or elasticity of the skin.
• agents that stimulate the proliferation of fibroblasts or keratinocytes and / or the differentiation of keratinocytes are particularly suitable for use in the prevention or treatment of cutaneous signs of aging, in particular the loss of firmness and / or elasticity of the skin.
• the agents stimulating the proliferation of fibroblasts may for example be chosen from plant proteins or polypeptides, extracted especially from soybeans (for example a soybean extract sold by LSN under the name Eleseryl SH-VEG 8 ® or marketed by Silab under the trade name Raffermine® ®); and plant hormones such as giberrellins and cytokinins.
• Agents stimulating the proliferation of keratinocytes include retinoids such as retinol and its esters, including retinyl palmitate; adenosine; phloroglucinol; nut cake extracts marketed by GATTEFOSSE; and extracts of Solanum tuberosum marketed by SEDERMA.
• retinoids such as retinol and its esters, including retinyl palmitate; adenosine; phloroglucinol; nut cake extracts marketed by GATTEFOSSE; and extracts of Solanum tuberosum marketed by SEDERMA.
• Agents stimulating the differentiation of keratinocytes include, for example, minerals such as calcium; a peptide extract of lupine such as the product sold by Silab under the trade name Structurine® ®; beta-sitosteryl sodium sulfate, such as that sold by SEPORGA under the trade name Phytocohesine® ®; and a water soluble extract of corn such as that marketed by Solabia under the trade name Phytovityl ®; a peptide extract of Voandzeia subterranea such as that marketed by Laboratoires Serobi unanimouss under the trade Filladyn LS 9397 ®; and lignans such as secoisoiariciresinol.
• minerals such as calcium
• a peptide extract of lupine such as the product sold by Silab under the trade name Structurine® ®
• beta-sitosteryl sodium sulfate such as that sold by SEPORGA under the trade name
• composition according to the invention comprising these compounds is preferably intended to be used for preventing or treating the cutaneous signs of aging.
• - myorelaxant or dermo-decontracting agents are preferably intended to be used for preventing or treating the cutaneous signs of aging.
• the muscle relaxant or dermo-decontracting agents that can be used in the composition according to the invention include alverine and its salts, manganese gluconate, diazepam, Argireline R hexapeptide marketed by LIPOTEC, certain secondary and tertiary carbonyl amines, adenosine. and its derivatives, as well as sapogenins and natural extracts, in particular WiId Yam, containing them, as well as extracts of Boswellia serrata.
• the composition according to the invention comprising these compounds is preferably intended to be used for preventing or treating the cutaneous signs of aging and in particular wrinkles.
• tensing agent a compound capable of exerting traction on the skin, which has the effect of temporarily blurring irregularities on the surface of the skin, such as wrinkles and fine lines.
• synthetic polymers such as polyurethane latices or acrylic-silicone latices, in particular those described in patent application EP-1038519, such as a grafted polydimethyl siloxane propylthio (methyl polyacrylate), propylthio (polymethacrylate) methyl) and propylthio (polyacrylic acid), or a polydimethyl siloxane grafted propylthio (isobutyl polymethacrylate) and propylthio (poly methacrylic acid).
• grafted silicone polymers are in particular sold by 3M under the trade names VS 80, VS 70 or LO 21,
• polymers of natural origin in particular (a) polyholosides, for example (i) in the form of starch derived especially from rice, maize, potato, cassava, peas, wheat, d oats, etc. or (H) in the form of carrageenans, alginates, agars, gellanes, cellulosic polymers and pectins, advantageously in aqueous dispersion of gel microparticles, and (b) the latexes constituted by the shellac resin, the gum of sandaraque, dammars, elemis, copals, cellulose derivatives, and mixtures thereof, (3) proteins and hydrolysates of vegetable proteins, in particular maize, rye, wheat, buckwheat, sesame, and other , peas, beans, lentils, soya and lupine,
• polyholosides for example (i) in the form of starch derived especially from rice, maize, potato, cassava, peas,
• wax microparticles chosen for example from Camauba, Candelila or Alfa waxes, (5) colloidal particles of inorganic filler having a number average diameter of between 0.1 and 100 nm, preferably between 3 and 30 nm, and chosen for example from: silica, silica-alumina composites, cerium oxide, zirconium oxide, alumina, calcium carbonate, barium sulfate, sodium sulfate calcium, zinc oxide and titanium dioxide.
• the compositions according to the invention comprising the above tensing agents are advantageously intended for the treatment of cutaneous signs of aging, in particular wrinkles and fine lines.
• anti-pollution agent any compound capable of trapping ozone, the mono- or polycyclic aromatic compounds such as benzopyrene and / or metals such as cobalt, mercury, cadmium and / or nickel.
• anti-radical agent any compound capable of trapping free radicals.
• vitamin C and its derivatives including ascorbyl glucoside; phenols and polyphenols, in particular tannins, ellagic acid and tannic acid; Epigallocatechin and natural extracts containing it; olive leaf extracts; tea extracts, especially green tea; anthocyanins; rosemary extracts; phenolic acids, in particular chorogenic acid; stilbenes, in particular resveratrol; sulfur-containing amino acid derivatives, in particular S-carboxymethylcysteine; ergothioneine; N-acetylcysteine; chelating agents such as N, N'-bis- (3,4,5-trimethoxybenzyl) ethylenediamine or a salt thereof, metal complexes or esters; carotenoids such as crocetin; and various raw materials such as arginine mixture ribonucleate histidine, mannitol, adeno
• tannins such as ellagic acid
• indole derivatives in particular indol-3-carbinol
• tea extracts especially green tea, extracts of water hyacinth or eichornia crassipes
• the water-soluble fraction of corn sold by Solabia under the trade name Phytovityl ® is sold by Solabia under the trade name Phytovityl ®.
• chelating agents such as EDTA, the pentasodium salt of ethylenediamine tetramethylene phosphonic acid, and N, N'-bis- ( 3,4,5-trimethoxybenzyl) ethylenediamine or a salt thereof, metal complexes or esters; phytic acid; chitosan derivatives; tea extracts, especially green tea; tannins such as ellagic acid; sulfur-containing amino acids such as cysteine; water hyacinth (Eichornia crassipes) extracts; and the water-soluble fraction of corn sold by Solabia under the trade name Phytovityl ®.
• EDTA the pentasodium salt of ethylenediamine tetramethylene phosphonic acid
• phytic acid chitosan derivatives
• tea extracts especially green tea
• tannins
• the anti-radical agents that can be used in the composition according to the invention comprise, in addition to certain anti-pollution agents mentioned above, vitamin E and its derivatives such as tocopheryl acetate; bioflavonoids; coenzyme Q10 or ubiquinone; certain enzymes such as catalase, superoxide dismutase and wheat germ extracts containing it, lactoperoxidase, glutathione peroxidase and quinone reductases; glutathione; benzylidene camphor; benzylcyclanones; substituted naphthalenones; pidolates; phytantriol; gamma-oryzanol; guanosine; lignans; and melatonin.
• vitamin E and its derivatives such as tocopheryl acetate; bioflavonoids; coenzyme Q10 or ubiquinone
• certain enzymes such as catalase, superoxide dismutase and wheat germ extracts containing
• the active agents acting on the microcirculation can be chosen from flavonoids, ruscogenins, esculosides, escin extracted from horse chestnuts, nicotinates, heperidine methyl chalcone, essential oils of lavender or rosemary, extracts of Ammi Visnaga.
• the amount of these assets can vary to a large extent.
• these active agents are present in a concentration ranging from 0.01 to 15% and preferably from 0.05 to 10% by weight relative to the total weight of the composition.
• the active agents concerned are those that act on cutaneous energetic metabolism, such as, for example, and without limitation, the synthesis of ATP, those that intervene on the respiratory chain of the cell or on energy reserves.
• Coenzyme Q10 ubiquinone
• cytochrome C 1 creatine or phosphocreatine there may be mentioned.
• compositions will be for cosmetic use and in particular for topical application to the skin and keratinous fibers, and more particularly to the scalp, the hair and eyelashes, they may be in any known galenic forms adapted to the mode of use, for example, those mentioned above.
• the composition for application to the scalp or the hair may be in the form of a hair care lotion, for example a daily or biweekly application, a shampoo or a hair conditioner, in particular Particular application bi-weekly or weekly, a liquid soap or solid daily scalp cleansing, a product shaping the hairstyle (lacquer, product for setting, styling gel) , a masking mask, a cream or a foaming gel for cleaning the hair. It can still be in the form of hair dye or mascara to be applied by brush or comb.
• the composition to which the invention applies may be in the form of a mascara, pigmented or not, to be applied to the brush on the eyelashes or on the hairs beard or mustache.
• composition according to the invention is in the form of hair cream or lotion, shampoo or hair conditioner, hair mascara or eyelash.
• the composition may contain another additional active ingredient that non-photosynthetic filamentous bacteria extract non-fruiting which may be hydrophilic and selected from proteins or hydrolysates of protein, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, plant extracts (those of Iridaceae or soya) and hydroxy acids (fruit acid , salicylic acid) ; or lipophilic and selected from retinol (vitamin A) and its derivatives including ester (retinol palmitate), tocopherol (vitamin E) and derivatives including ester (acetate or tocopherol palmitate), essential fatty acids, ceramides, essential oils, salicylic acid derivatives such as 5-n-octanoylsalicylic acid, esters of hydroxy acids, phospholipids such as lecithin, and mixtures thereof.
• non-photosynthetic filamentous bacteria extract non-fruiting which may be hydrophilic and selected from proteins or hydrolysates
• the non-photosynthetic filamentous bacterial extract non-fruiting at least one additional active compound promoting the regrowth and / or limiting the fall of the keratinous fibers and in particular the hair.
• additional compounds are selected in particular from lipoxygenase inhibitors as described in EP 0648488, the bradykinin inhibitors described especially in I 1 EP 0,845,700, prostaglandins and derivatives thereof including those described in WO 98/33497, WO 95/11003 JP 97-100091, JP 96-134242, prostaglandin receptor agonists or antagonists, non-prostanoid prostaglandin analogs as described in EP 1 175 891 and EP 1 175 890, WO 01/74307, WO 01/74313, WO 01/74314, WO 01/74315 or WO 01/72268, their mixtures.
• vasodilators As other additional active compounds promoting the growth of keratinous fibers and in particular hair that may be present in the composition according to the invention, mention may be made of vasodilators, antiandrogens, cyclosporins and their analogues, antimicrobials and antifungals, anti-inflammatories, retinoids, alone or in a mixture.
• Vasodilators that may be used include potassium channel agonists (different from those of the invention) including minoxidil and the compounds described in US 3,382,247, US 5,756,092, US 5,772,990, US 5,760,043, US 5,466,694, US 5,438,058, US 4,973,474. , cromakalim, nicorandil and diaxozide, alone or in combination.
• Usable antiandrogens include, but are not limited to, steroidal or nonsteroidal 5 ⁇ -reductase inhibitors, such as finasteride and the compounds described in US 5,516,779, cyprosterone acetate, azelaic acid, its salts and derivatives and the compounds described in US 5,480,913. , flutamide and the compounds described in US Patents 5,411,981, US 5,565,467 and US 4,910,226.
• the antimicrobial or antifungal compounds may be chosen from selenium derivatives, ketoconazole, octopirox, triclocarban, triclosan, pyrithione zinc, itraconazole, asiatic acid, hinokitiol, mipirocine, tetracyclines, especially erythromycin and the compounds described in EP 0680 745, clinycin hydrochloride, benzoyl or benzyl peroxide and minocycline.
• the anti-inflammatory drugs may be selected from steroidal anti-inflammatory agents such as glucocorticoids, corticosteroids (for example: hydrocortisone) and nonsteroidal anti-inflammatory drugs such as glycyrrhetinic acid and ⁇ -bisabolol, benzydamine, acid salicylic acid and the compounds disclosed in I 1 EP 0770399, WO 94/06434 and FR 2 268 523.
• steroidal anti-inflammatory agents such as glucocorticoids, corticosteroids (for example: hydrocortisone) and nonsteroidal anti-inflammatory drugs such as glycyrrhetinic acid and ⁇ -bisabolol, benzydamine, acid salicylic acid and the compounds disclosed in I 1 EP 0770399, WO 94/06434 and FR 2 268 523.
• the retinoids may be selected from Nsotretinoin, acitretin and tazarotene.
• aminexil 6-0- [(9Z, 12Z) -octadeca-9,12-dienoyl] hexapyranose, benzalkonium chloride, benzethonium chloride, phenol, oestradiol, chlorpheniramine maleate, chlorophyllin derivatives, cholesterol, cysteine, methionine, menthol, peppermint oil, calcium panthotenate, panthenol, resorcinol, protein kinase C activators, glycosidase inhibitors, glycosaminoglycanase inhibitors, pyroglutamic acid esters, hexosaccharide or acyl-hexosaccharic acids, substituted
• composition according to the invention can be applied to the alopecic areas of the scalp and hair of an individual, and possibly left in contact for several hours and possibly rinsed.
• Vitreoscilla filiformis ATCC 15551
• ATCC 15551 Vitreoscilla filiformis (ATCC 15551) bacteria, frozen or dried with acetone in the form of a powder, are added 25 ml of buffer 50 mM Na phosphate pH7 containing
• the bacterial suspension is then placed in a bath at 70 ° C. and an equal volume of 90% (w / v) phenol preheated to 70 ° C. is added to it; - It is cooled by stirring for 15 min in an ice bath;
• a marked interface is between the aqueous and phenolic phases.
• the aqueous phase contains the lipopolysaccharides, after dialysis against water, this phase is lyophilized.
• Purification of crude lipopolysaccharides 20 to 35 mg of lipopolysaccharides / ml of distilled water are centrifuged at low speed (1100 g, 5 min). The supernatant obtained is then centrifuged at high speed (105 000 g, 16 h, 4 ° C.). The pellet is suspended in water, the centrifugation is repeated until purified lipopolysaccharides are obtained. The final pellet is resuspended in water and freeze-dried.
• the immunostimulatory activity is tested as follows: human peripheral blood cells are cultured in the presence of an RPMI culture medium supplemented with L-Glutamine (2 mM), penicillin / streptomycin (50 ⁇ g / 50Ui / ml), and fetal calf serum (10%). Extracts of Vitreoscilla filiformis are added at different concentrations (10 to 0.05mM) as well as phytohemagglutin (PHA at 5 * G / ml), a positive control of lymphocyte proliferation. After 3 days of culture the proliferation is revealed by BrdU labeling.
• Composition 1 Cleansing lotion for the face
• composition 2 »Gel for the facial care
• Composition 3 "Restorative Sleep Cream"
• Polysorbate 60 (Tween 60 sold by the company ICI) 1.00
• composition 4 Anti-hair loss hair lotion
• This lotion is applied to the scalp, once or twice a day, at a rate of 1 ml per application, by gently massaging the scalp to penetrate the active ingredient. The hair is then dried in the open air. This lotion helps reduce hair loss and promote their regrowth.
• Composition 5 Wax / water mascara
• This mascara is applied on eyelashes as a classic mascara with a mascara brush.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Dermatology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Tropical Medicine & Parasitology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Birds (AREA)
• Molecular Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Biotechnology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Cosmetics (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=36953732

Family Applications (1)

Country Status (2)

Cited By (1)

Families Citing this family (3)

Family Cites Families (6)

• 2006
  • 2006-03-10 EP EP06726069A patent/EP1863505A2/de not_active Ceased
  • 2006-03-10 WO PCT/FR2006/000538 patent/WO2006095098A2/fr not_active Ceased

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events